Year: 1998
Type: letter
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background The Lennox–Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat. Dose-related drug toxicity is common. Methods We conducted a double-blind, placebo-controlled trial of the antiepileptic drug lamotrigine in patients with the Lennox–Gastaut syndrome. Eligible patients had more than one type of predominantly generalized seizure, including tonic–clonic, atonic, tonic, and major myoclonic, and had seizures on average at least every other day. After a 4-week base-line period in which all participants received placebo, we randomly assigned 169 patients (age range, 3 to 25 years) to 16 weeks of lamotrigine (n = 79) or placebo (n = 90) in addition to their other antiepileptic drugs. Results The median frequency of all major seizures changed from base-line levels of 16.4 and 13.5 per week in the lamotrigine and placebo groups, respectively, to 9.9 and 14.2 per week after 16 weeks of treatment (P = 0.002). Thirty-three percent of the patients in the lam...
Source: New England Journal of Medicine
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2321582280
